Reaction
Glomerulonephritis Rapidly Progressive reporting signals
As of the last recalculation, Glomerulonephritis Rapidly Progressive appears in 1,078 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is ATOVAQUONE (PRR 16.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Atovaquone | 7 | 16.9 | 16.9 |
| Minocycline | 10 | 16.7 | 16.7 |
| Febuxostat Tablets 40 Mg | 8 | 15.3 | 15.3 |
| Febuxostat Tablets 80 Mg | 8 | 15.3 | 15.3 |
| Labetalol | 9 | 13.1 | 13.1 |
| Febuxostat | 9 | 10.4 | 10.5 |
| Pemetrexed | 10 | 9.1 | 9.1 |
| Romosozumab-Aqqg | 5 | 7.1 | 7.1 |
| Gefitinib | 3 | 6.4 | 6.4 |
| Nivolumab | 31 | 6.3 | 6.3 |
| Ipilimumab | 13 | 5.9 | 5.9 |
| Durvalumab | 6 | 5.7 | 5.7 |